Rigontec: Merck to Acquire Rigontec

Merck has entered into an agreement to acquire Rigontec, a biotechnology company developing cancer immunotherapies, for €115 million upfront and as much as €349 million in milestone payments. Rigontec’s lead candidate, RGT100, is currently in Phase I development for the treatment of various tumors